Skip to main content
Equibles
ORMP logo

ORMP · Oramed Pharmaceuticals Inc. · Metrics

Track ORMP — free

Use ORMP with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ORMP.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.66 -0.10 (-2.10%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$193.84M
Shares
41.60M

ORMP metrics

69 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$4.66
Market cap
$193.84M

Price action

20 metrics
Price change (1W)
-7.0%
Price change (30D)
+4.0%
Price change (3M)
+20.4%
Price change (6M)
+35.9%
Price change (YTD)
+63.5%
Price change (1Y)
+91.8%
Trailing year
Price change (5Y)
-76.1%
52-week high
$5.34
52-week low
$2.19
Change from 52-week high
-12.7%
Change from 52-week low
+112.8%
Annualized volatility
55.5%
Annualized volatility (3M)
56.9%
Beta
1.1
RSI (14D)
47.1
Price vs SMA 50
+4.2%
Price vs SMA 200
+23.2%
Avg volume (3M)
300,849
Relative volume
0.5
Average dollar volume
$1.38M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
41.60M

Valuation

12 metrics
P / E (TTM)
1.1
Trailing earnings · reciprocal yield 88.6%
PEG ratio
0.0
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.6
reciprocal yield 163.8%
FCF yield
-2.7%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
90.2%

Historical valuation

8 metrics
P / E historical average (3Y)
5.8×
reciprocal yield 17.3%
P / E historical average (5Y)
5.8×
reciprocal yield 17.3%
EV / revenue historical average (3Y)
72.5×
reciprocal yield 1.4%
EV / revenue historical average (5Y)
60.5×
reciprocal yield 1.7%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
5.4%
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
$0.25
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
2026-01-16

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
0.7%
Operating margin
-754.4%
Trailing 12 months
Net margin
3,202.5%
Gross profit (TTM)
—
Operating profit (TTM)
−$14.52M
Net income (TTM)
$174.87M
Trailing 12 months
Diluted EPS (TTM)
$4.13
FCF margin
—
Effective tax rate
20.6%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$5.09

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
+488.2%
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
+493.5%
Shares change YoY
-0.3%
Year over year · fewer shares
Revenue CAGR (3Y)
-9.6%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
55.1%
Return on assets
47.3%
Debt / equity
—
Current ratio
5.0
EBITDA (TTM)
−$15.37M
Free cash flow (TTM)
−$5.21M
Quick ratio
5.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$15.24M
Total assets
$369.64M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$5.21M
Capital expenditures (TTM)
$9,000
R&D (TTM)
$4.74M
SG&A (TTM)
—
Stock compensation (TTM)
$6.13M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
84
13F filer change QoQ
+20
Institutional ownership
40.4%

Short interest

3 metrics
Short interest
2.8%
Latest settlement · 4.3 days to cover
Days to cover
4.3d
Short-squeeze score
52 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$942,175
Insider-sentiment score
22 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1176309 CUSIP 68403P203 13F (30d) 26 filings 26 filers Visit website Investor relations